John Ratliff Joins T3D Therapeutics’ Advisory Board
John Ratliff recently retired from Quintiles as President and Chief Operating Officer. He led Quintiles’ Global Services organization with it’s clinical research, commercial, consulting, lab operations and was a member of the company’s Board of Directors. John helped...
T3D Therapeutics, Inc. Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer’s Patients
Phase 2a Clinical Trial of a Novel Nuclear Receptor Agonist in Alzheimer’s patients expected to initiate in 3Q2015. Read More
T3D Therapeutics Selected by the Alzheimer’s Association to Present Pre-Clinical Results of T3D-959 at the 2015 Alzheimer’s Association International Conference.
T3D Therapeutics, Inc. has been selected by the Alzheimer’s Association to present pre-clinical results of T3D-959 at the upcoming Alzheimer’s Association International Conference (AAIC) in Washington, DC, July 18-23, 2015. The poster presentation will provide details...
T3D Therapeutics adds Dr. Jason Kralic, Dr. Stuart Hobbs and Wesley Protheroe to its Advisory Board
T3D Therapeutics announced the addition of three new members to its Advisory Board complementing Alzheimer’s disease and CNS expertise with pharmaceutical licensing, clinical development and business acumen; Jason Kralic Ph.D., Stuart Hobbs, Pharm.D., and Wesley...
T3D Therapeutics, Inc. Awarded SBIR Phase 2 Grant From The National Institute On Aging For Alzheimer’s Disease Drug Testing
NIA/NIH grant support for Phase 2a clinical testing of a new, potentially disease-modifying therapy tor Alzheimer's disease. Read More
T3D Therapeutics Selected as a ‘Showcase’ Company to Present at the 2015 CED Life Science Conference
T3D Therapeutics was one of only thirteen companies selected to participate in this year’s CED Life Science Conference Showcase, March 3-4, 2015. CED received over 70 applicants and the Selection Committee felt that T3D represented one of the best new companies in the...
T3D Therapeutics is Awarded a Competitive Strategic Research Loan from the North Carolina Biotechnology Center
T3D Therapeutics announced it has been awarded a competitive $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center. The SRL Program funds research to advance development of commercially viable technologies/products. Through the SRL...
T3D Therapeutics Reports Successful Pre-IND Meeting with the FDA
T3D Therapeutics announced today that it had a successful Type B Pre-Investigational New Drug (“Pre-IND) meeting on April 1st with the US Food and Drug Administration’s Division of Neurology Products, for T3D-959, a novel nuclear receptor agonist for the treatment of...
T3D Therapeutics Completes Series A1/A2 Preferred Equity Offering
T3D Therapeutics announced that is successfully completed a Series A1/A2 Preferred Equity Offering pursuant to rule 506 regulation D of the Securities Act of 1933. New and current angel investors participated.
T3D Therapeutics adds Dr. Suzanne de la Monte to Its Advisory Board
T3D Therapeutics announced the addition of Dr. Suzanne de al Monte to its Advisory Board. Suzanne de la Monte, MD, MPH, is a physician scientist who directs basic and translational research in the laboratory and performs clinical service work in Neuropathology. Her...